Published in Dement Geriatr Cogn Disord on July 04, 2007
Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections. Br J Pharmacol (2012) 1.26
Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease. CMAJ (2008) 1.21
Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther (2013) 1.17
Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clin Interv Aging (2009) 1.14
Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease. Neurotox Res (2013) 0.96
Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementias. Dement Geriatr Cogn Dis Extra (2012) 0.96
Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer's disease. Dement Geriatr Cogn Disord (2009) 0.96
From single target to multitarget/network therapeutics in Alzheimer's therapy. Pharmaceuticals (Basel) (2014) 0.92
Update on the use of memantine in Alzheimer's disease. Neuropsychiatr Dis Treat (2009) 0.87
Therapy for Alzheimer's Disease: How Effective are Current Treatments? Ther Adv Neurol Disord (2009) 0.85
Efficacy of memantine, donepezil, or their association in moderate-severe Alzheimer's disease: a review of clinical trials. ScientificWorldJournal (2013) 0.81
Memantine in moderate to severe Alzheimer's disease: an observational post-marketing study. J Neural Transm (Vienna) (2011) 0.80
Protection from glutamate-induced excitotoxicity by memantine. Ann Biomed Eng (2011) 0.78
Memantine prevents sensitivity to excitotoxic cell death of rat cortical neurons expressing human truncated tau protein. Cell Mol Neurobiol (2009) 0.76
Nonmedical treatment of patients with dementia. Innov Clin Neurosci (2011) 0.75
Effectiveness and safety of generic memantine hydrochloride manufactured in China in the treatment of moderate to severe Alzheimer's disease: a multicenter, double-blind randomized controlled trial. Shanghai Arch Psychiatry (2013) 0.75
Management of patients with Alzheimer's disease: pharmacological treatment and quality of life. Ther Adv Chronic Dis (2012) 0.75
An open-label, multicenter observational study for patients with Alzheimer's disease treated with memantine in the clinical practice. Dement Geriatr Cogn Dis Extra (2011) 0.75
Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately? Open Neurol J (2009) 0.75
Disease Progression in Mild Dementia due to Alzheimer Disease in an 18-Month Observational Study (GERAS): The Impact on Costs and Caregiver Outcomes. Dement Geriatr Cogn Dis Extra (2017) 0.75
Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med (2010) 6.81
What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry (2006) 1.48
Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int J Neuropsychopharmacol (2004) 0.98
A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr Med Res Opin (2005) 0.91
Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder. Int Clin Psychopharmacol (2008) 0.88
Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes. Ann Clin Psychiatry (2005) 0.84
Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol (2004) 0.84